Grace Therapeutics, Inc. (GRCE)
NASDAQ · Manufacturing · Pharmaceutical preparations
GRCE price, last 12 months
Key stats
- Previous close
- $2.16
- Open
- $2.14
- Day range
- $2.10 – $2.14
- 52-week range
- $1.79 – $5.18
- Volume
- 80.2K
- Avg volume (20 days)
- 152.8K
- Market cap
- $44.6M
Performance
Technicals and fundamentals
About Grace Therapeutics, Inc.
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $44.6M